TERN
Terns Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$52.95
−0.03%Aug 16, 2026, 13:46 UTC
Merck reported first-half 2026 results with a net loss of $5.575 billion due to a one-time acquisition charge, and total revenue of $32.893 billion, up 5% year-over-year.
Source:Aug 4, 2026, 10:34 UTC
Merck incurred a charge related to its acquisition of Terns Pharmaceuticals, which affected its profit guidance.
Jul 31, 2026, 18:10 UTC
Merck acquired Terns Pharmaceuticals and Cidara Therapeutics to broaden its oncology and virology portfolios.
Source:Jul 2, 2026, 17:55 UTC
Merck KGaA acquired Terns Pharmaceuticals for $6.7 billion.
Source: